spacer
home > pmps > spring 2017 > supply and demand
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Supply and Demand

The R&D of a new molecular entity (NME) is a constant battle and requires tradeoffs between the budget set by the organisation, product development goals, personnel available and the public health issues of the country. The total worldwide R&D expenditure of pharmaceutical and biotechnology companies increased from $108 billion in 2006 to $141 billion in 2015. Paul et al reported that:
  • Drug discovery and preclinical development account for 33% of the total cost per NME ($281 million)
  • Clinical development (Phase 1 to submission) represents 63% ($548 million)
  • Submission to launch costs 5% of the overall expenditures per NME ($44 million)
Discovery research lasts four and a half years; preclinical testing continues for a further year; the three clinical development phases take 1.5, 2.5 and 2.5 years respectively; and the phase from submission to launch requires another 18 months. The above is a clear testimonial of the significance of the whole clinical research process that accounts for the majority of the cost and time involved in bringing an innovation to market.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
With over 19 years of clinical research experience in global project management and CTS, Partha Chatterjee is Head of Clinical Research and Clinical Trial Supplies Management at SIRO Clinpharm. A postgraduate in Microbiology from the Institute of Science, India, he was one of the earliest members of the company and his knowledge and expertise have been pivotal in managing numerous key clinical trials across therapeutic areas such as oncology, nephrology, endocrinology and infectious diseases.
spacer
Partha Chatterjee
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Oxford Genetics licenses SnapFast™ expression vectors to Twist Bioscience

November 16, 2017, Oxford, England and San Francisco, US. – Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced today a new licensing agreement with Twist Bioscience Corporation, a company enabling customers to succeed through its offering of rapid, high-quality synthetic DNA. Oxford Genetics will supply Twist Bioscience with its SnapFast™ technology platform to provide a broad range of application-specific expression vectors which Twist Bioscience will use to clone synthesized DNA for its diverse customer base.
More info >>

White Papers

Protein Therapeutics

Reading Scientific Services Ltd (RSSL)


More info >>

 
Industry Events

Outsourcing in Clinical Trials Southeast 2018

13-14 March 2018, Durham, North Carolina

This year’s Outsourcing in Clinical Trials event builds on last year’s incredibly successful conference which will once again be returning to North Carolina with the aim of supporting trial sponsors and solution providers in the RTP and neighboring regions, ensuring trials are delivered on time and partnerships are bettered.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement